Skip to main content
. 2017 Jul 25;55(8):2431–2438. doi: 10.1128/JCM.00318-17

TABLE 1.

General demographic details of the study population

Characteristic No. (%) at site (location):
1 (NY) 2 (TX) 3 (MO) 4 (ON) All sites
Sex
    Male 375 (46.2) 134 (41.0) 200 (51.7) 459 (48.1) 1,168 (47.1)
    Female 436 (53.8) 193 (59.0) 187 (48.3) 495 (51.9) 1311 (52.9)
    Total 811 327 387 954 2479
Age (years)
    <1 37 (4.6) 32 (9.8) 102 (26.4) 263 (27.6) 434 (17.5)
    1–5 29 (3.6) 29 (8.9) 62 (16.0) 103 (10.8) 223 (9.0)
    >5–21 29 (3.6) 49 (15.0) 64 (16.5) 103 (10.8) 245 (9.9)
    >21–65 316 (39.0) 131 (40.1) 124 (32.0) 274 (28.7) 845 (34.1)
    >65 400 (49.3) 86 (26.3) 35 (9.0) 211 (22.1) 732 (29.5)
    Total 811 327 387 954 2,479
Subject status or placement
    Outpatient 147 (18.1) 167 (51.1) 85 (22.0) 64 (6.7) 463 (18.7)
    Hospitalized 484 (59.7) 111 (33.9) 158 (40.8) 546 (57.2) 1,299 (52.4)
    Emergency department 180 (22.2) 48 (14.7) 144 (37.2) 344 (36.1) 716 (28.9)
    Long-term care facility 0 (0.0) 1 (0.3) 0 (0.0) 0 (0.0) 1 (0.0)
    Total 811 327 387 954 2479
Immune status
    Immunocompromiseda 177 (21.8) 87 (26.6) 0 (0.0) 84 (8.8) 348 (14.0)
    Immunocompetent 628 (77.4) 239 (73.1) 0 (0.0) 870 (91.2) 1,737 (70.1)
    Not determined 6 (0.7) 1 (0.3) 387 (100.0) 0 (0.0) 394 (15.9)
    Total 811 327 387 954 2,479
a

Defined as patients with HIV or AIDS, transplant, oncology, or diabetes.